Early Access — free while we kick the tires
EdgarHawk

CNSP CNS Pharmaceuticals, Inc. Insider Trading

Latest: Director Bought $34K of Shares · May 2026

The only insider purchase or sale analyzed for CNS Pharmaceuticals, Inc. (CNSP) so far is Director Charles Faith L., who bought $34K in May 2026.

1 filing analyzed · Latest 2026-05-20

Get alerts for CNSP

Free Form 4 email alerts, scored for significance — see how.

Buys
1
Sells
0
Insiders
1
Direction
Net buying

CNS Pharmaceuticals, Inc. leadership

CEO
Rami Levin — CHIEF EXECUTIVE OFFICER
CFO
Steve O’Loughlin — CHIEF FINANCIAL OFFICER
Chair
Faith L. Charles — Director and Chair of the Board of Directors

Historically, medium-priority insider buys have outperformed the S&P 500 by a median ~1% over the 30 days after the trade — the edge is concentrated in that first month (n ≈ 7,162, 2024-2026). Past results don't predict the future. How we measure this ↗

May 2026
2026-05-20
medium
7,100 shares
$34,002
@ $4.79
Significance 4

Director Charles Faith L. buys 7,100 CNSP shares at $4.79; company unprofitable with $-4.9M net income

Charles Faith L., a director, purchased 7,100 shares at $4.79 on 2026-05-18, representing his first holding in the security. The purchase occurs in an unprofitable company: CNS Pharmaceuticals reported net income of $-4,937,046.00 over its most recent full fiscal year, with a market cap of $6,985,726.22. The stock is currently 71.1% below its 52-week high of $16.56, having rallied 88.2% over the past 30 days. Across his cross-ticker open-market history, the insider has achieved a 100.00% 90-day win rate with an average 90-day return of 53.4%, though this track record provides limited predictive value for CNSP-specific outcomes given the absence of prior same-ticker history.

More Chemicals and Allied Products companies